Hepatitis C Virus Nucleotide Inhibitors PSI-352938 and PSI-353661 Exhibit a Novel Mechanism of Resistance Requiring Multiple Mutations within Replicon RNA

Inhibition of Hepatitis C Virus Replicon RNA Synthesis by PSI-352938, a Cyclic Phosphate Prodrug of β-d-2′-Deoxy-2′-α-Fluoro-2′-β-C-Methylguanosine

(2011) Angela M. Lam et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

INX-08189, a Phosphoramidate Prodrug of 6-O-Methyl-2′-C-Methyl Guanosine, Is a Potent Inhibitor of Hepatitis C Virus Replication with Excellent Pharmacokinetic and Pharmacodynamic Properties

(2011) John H. Vernachio et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661

(2011) Phillip A. Furman et al.   ANTIVIRAL RESEARCH

1356 QUADRUPLE THERAPY WITH BMS-790052, BMS-650032 AND PEG-IFN/RBV FOR 24 WEEKS RESULTS IN 100% SVR12 IN HCV GENOTYPE 1 NULL RESPONDERS

(2011) A. Lok et al.   JOURNAL OF HEPATOLOGY

1372 ONCE DAILY PSI-7977 PLUS PEG-IFN/RBV IN HCV GT1: 98% RAPID VIROLOGIC RESPONSE, COMPLETE EARLY VIROLOGIC RESPONSE: THE PROTON STUDY

(2011) D.R. Nelson et al.   JOURNAL OF HEPATOLOGY

A Comprehensive Structure-Function Comparison of Hepatitis C Virus Strain JFH1 and J6 Polymerases Reveals a Key Residue Stimulating Replication in Cell Culture across Genotypes

(2011) M. Schmitt et al.   JOURNAL OF VIROLOGY

RG7128 Alone or in Combination with Pegylated Interferon‐α2a and Ribavirin Prevents Hepatitis C Virus (HCV) Replication and Selection of Resistant Variants in HCV‐Infected Patients

(2010) Sophie Le Pogam et al.   JOURNAL OF INFECTIOUS DISEASES

Discovery of a β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus

(2010) Michael J. Sofia et al.   JOURNAL OF MEDICINAL CHEMISTRY

Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection

(2009) Christoph Sarrazin et al.   GASTROENTEROLOGY

Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs)

(2009) T. L. Kieffer et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Antiviral resistance and specifically targeted therapy for HCV (STAT-C)

(2009) A. J. V. Thompson et al.   JOURNAL OF VIRAL HEPATITIS

Structural and Functional Analysis of Hepatitis C Virus Strain JFH1 Polymerase

(2009) P. Simister et al.   JOURNAL OF VIROLOGY

Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479

(2008) S. Ali et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

(2008) M. F. McCown et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Resistance mechanisms in HCV: from evolution to intervention

(2008) Arthur Y Kim et al.   Expert Review of Anti-Infective Therapy

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

(2008) Thomas Kuntzen et al.   HEPATOLOGY